CRISPR Therapeutics AG
CRSP
Price:
$40.48
Market Cap:
$3.46B
CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA. The company has a portfolio of therapeutic programs across a range of disease areas, including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company's lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from transfusion-dependent beta-thalassemia or severe sickle cell d...[Read more]
Industry
Biotechnology
IPO Date
2016-10-19
Stock Exchange
NASDAQ
Ticker
CRSP
PE Ratio
[-14.51]
ROE
[-12.15%]
Current Ratio
[21.64]
Dividend Yield
[0%]
Enterprise Value
[3.46B]
Dividend History
The ROE as of December 2024 (TTM) for CRISPR Therapeutics AG (CRSP) is -12.15%
According to CRISPR Therapeutics AG’s latest financial reports and current stock price. The company's current ROE is -12.15%. This represents a change of 316.79% compared to the average of -2.92% of the last 4 quarters.
CRISPR Therapeutics AG (CRSP) Historical ROE (quarterly & annually)
How has CRSP ROE performed in the past?
The mean historical ROE of CRISPR Therapeutics AG over the last ten years is 5.50%. The current -12.15% ROE has changed -321.10% with respect to the historical average. Over the past ten years (40 quarters), CRSP's ROE was at its highest in in the December 2015 quarter at 42.22%. The ROE was at its lowest in in the June 2019 quarter at -14.60%.
Average
5.50%
Median
-9.06%
Minimum
-42.07%
Maximum
95.55%
CRISPR Therapeutics AG (CRSP) ROE by Quarter and Year
Discovering the peaks and valleys of CRISPR Therapeutics AG ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 265.22%
Maximum Annual ROE = 95.55%
Minimum Annual Increase = -394.55%
Minimum Annual ROE = -42.07%
| Year | ROE | Change |
|---|---|---|
| 2023 | -8.16% | -76.47% |
| 2022 | -34.67% | -320.26% |
| 2021 | 15.74% | -175.08% |
| 2020 | -20.96% | -394.55% |
| 2019 | 7.12% | -116.92% |
| 2018 | -42.07% | 15.59% |
| 2017 | -36.39% | 265.22% |
| 2016 | -9.96% | -111.23% |
| 2015 | 88.77% | -7.10% |
CRISPR Therapeutics AG (CRSP) Average ROE
How has CRSP ROE performed in the past?
The current ROE of CRISPR Therapeutics AG (CRSP) is greater than its 3-year, greater than its 5-year, and less than than its 10-year historical averages
3-year avg
-9.03%
5-year avg
-8.19%
10-year avg
5.50%
CRISPR Therapeutics AG (CRSP) ROE vs. Peers
How is CRSP’s ROE compared to its peers?
CRISPR Therapeutics AG’s ROE is greater than Beam Therapeutics Inc. (-16.22%), greater than Editas Medicine, Inc. (-80.13%), greater than Caribou Biosciences, Inc. (-45.46%), greater than Verve Therapeutics, Inc. (-35.23%), greater than Intellia Therapeutics, Inc. (-51.97%), greater than Fate Therapeutics, Inc. (-45.88%), less than Regeneron Pharmaceuticals, Inc. (16.85%), less than Novo Nordisk A/S (86.40%), less than Sarepta Therapeutics, Inc. (11.83%), greater than CohBar, Inc. (-58.44%), greater than Hepion Pharmaceuticals, Inc. (-505.74%), greater than Rain Therapeutics Inc. (-41.33%), less than Krystal Biotech, Inc. (6.34%), less than AVROBIO, Inc. (29.68%),
| Company | ROE | Market cap |
|---|---|---|
| -16.22% | $2.38B | |
| -80.13% | $103.19M | |
| -45.46% | $162.09M | |
| -35.23% | $499.52M | |
| -51.97% | $1.23B | |
| -45.88% | $189.06M | |
| 16.85% | $77.29B | |
| 86.40% | $377.66B | |
| 11.83% | $11.53B | |
| -58.44% | $1.57M | |
| -505.74% | $3.48M | |
| -41.33% | $44.01M | |
| 6.34% | $4.63B | |
| 29.68% | $5.24M |
Build a custom stock screener for CRISPR Therapeutics AG (CRSP) and other stocks
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like CRISPR Therapeutics AG using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
CRISPR Therapeutics AG (CRSP) and other stocks custom spreadsheet templates
The easiest way to analyze a company like CRISPR Therapeutics AG or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
Frequently asked questions❓
What is the ROE?
How can you use the ROE?
What is CRISPR Therapeutics AG's ROE?
How is the ROE calculated for CRISPR Therapeutics AG (CRSP)?
What is the highest ROE for CRISPR Therapeutics AG (CRSP)?
What is the 3-year average ROE for CRISPR Therapeutics AG (CRSP)?
What is the 5-year average ROE for CRISPR Therapeutics AG (CRSP)?
How does the current ROE for CRISPR Therapeutics AG (CRSP) compare to its historical average?